![Puma Biotechnology: Nerlynx Peak Sales Estimates Have Come Down, But The Intense Selling Still Makes This A Buy (NASDAQ:PBYI) | Seeking Alpha Puma Biotechnology: Nerlynx Peak Sales Estimates Have Come Down, But The Intense Selling Still Makes This A Buy (NASDAQ:PBYI) | Seeking Alpha](https://static.seekingalpha.com/uploads/2019/5/49102172_15591559956443_rId6.png)
Puma Biotechnology: Nerlynx Peak Sales Estimates Have Come Down, But The Intense Selling Still Makes This A Buy (NASDAQ:PBYI) | Seeking Alpha
![PUMA® - PUMA publishes preliminary results for the first quarter 2018 and slightly raises full-year guidance for 2018 PUMA® - PUMA publishes preliminary results for the first quarter 2018 and slightly raises full-year guidance for 2018](https://cdn.about.puma.com/-/media/images/newsroom/corporate-news/m-07_q1-prelim.jpg?as=1&h=384&iar=1&w=768&rev=751ad9573acd46eeb198133c1cd0853f&hash=7A75BBEEC709624E4DC83BBF7D89A6CF)
PUMA® - PUMA publishes preliminary results for the first quarter 2018 and slightly raises full-year guidance for 2018
![PUMA® - PUMA publishes preliminary results for the first quarter 2018 and slightly raises full-year guidance for 2018 PUMA® - PUMA publishes preliminary results for the first quarter 2018 and slightly raises full-year guidance for 2018](https://cdn.about.puma.com/-/media/images/authors/m-33-portrait-johan-kuhlo.jpg?as=1&h=288&iar=1&w=288&rev=d340ba1e09044ed285461cf8ca69389d&hash=3FB4C67F6FDED7D5ACCEE262FD66D548)